Line

With its long-anticipated acquisition of Horizon Therapeutics wrapped up last month, Thousand Oaks pharma giant Amgen Inc. is incorporating Horizon’s drug development programs into a new business line for rare disease therapies. Meanwhile, along its more traditional business lines, Amgen late last month won approval from the United States Food and Drug Administration to market […]